Wang Zanzan, Li Dan, Lu Lingling, Xu Zhijuan, Ouyang Guifang, Sun Yongcheng
Department of Hematology, The First Affiliated Hospital of Ningbo University, Ningbo, China.
Key Laboratory of Digital Technology in Medical Diagnostics of Zhejiang Province, Dian Diagnostics Group Co, Ltd, Hangzhou, China.
Open Forum Infect Dis. 2024 Jul 12;11(8):ofae393. doi: 10.1093/ofid/ofae393. eCollection 2024 Aug.
, a microsporidium, has risen to prominence as an opportunistic pathogen, particularly afflicting individuals who are immunocompromised with conditions such as rheumatoid arthritis, organ transplantation, and hematologic malignancy. Surprisingly, despite its recognized impact, the identification of in ascitic fluid has not been documented. As such, we pinpointed as the probable instigator of ascitic accumulation in a patient with a history of acute myeloid leukemia and extended periods of immunosuppressive therapy. For this patient, there were no signs of -related infections (eg, myositis), vocal cord involvement, or disseminated infection. The presence of was finally identified by next-generation metagenomic sequencing analysis of the ascitic fluid. Clinical presentation was characterized by elevated C-reactive protein levels (110.7 mg/L), diminished platelet count (48 × 10/L), abdominal distension secondary to ascitic fluid accumulation, and lower limb pain, and it showed marked improvement following a 4-day regimen of sulfamethoxazole/trimethoprim and albendazole. Despite this promising response, the patient succumbed to aspiration of vomitus. This case underscores the importance of considering rarer organisms, such as infection, in patients who are immunocompromised and present with unexplained ascites accumulation. It highlights the potential effectiveness of sulfamethoxazole/trimethoprim and albendazole in managing such cases. Further research is warranted to elucidate optimal management strategies and improve outcomes in similar clinical scenarios.
作为一种微孢子虫,已作为一种机会性病原体而受到关注,尤其折磨患有类风湿性关节炎、器官移植和血液系统恶性肿瘤等疾病的免疫功能低下个体。令人惊讶的是,尽管其影响已得到认可,但在腹水液中鉴定该病原体的情况尚未见报道。因此,我们确定该病原体是一名有急性髓细胞白血病病史且长期接受免疫抑制治疗患者腹水积聚的可能诱因。对于该患者,没有该病原体相关感染(如肌炎)、声带受累或播散性感染的迹象。最终通过腹水液的下一代宏基因组测序分析确定了该病原体的存在。临床表现的特征为C反应蛋白水平升高(110.7 mg/L)、血小板计数减少(48×10⁹/L)、因腹水积聚导致的腹胀以及下肢疼痛,在接受4天的磺胺甲恶唑/甲氧苄啶和阿苯达唑治疗后症状有明显改善。尽管有这种良好的反应,但患者因呕吐物误吸而死亡。该病例强调了在免疫功能低下且出现不明原因腹水积聚的患者中考虑罕见病原体感染(如该病原体感染)的重要性。它突出了磺胺甲恶唑/甲氧苄啶和阿苯达唑在处理此类病例中的潜在有效性。有必要进行进一步研究以阐明最佳管理策略并改善类似临床情况的结果。